NCT02768701View on ClinicalTrials.gov

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 18, 2016

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2023

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Pembrolizumab

Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.

DRUG

Cyclophosphamide

A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.

Trial Locations (5)

15213

University of Pittsburgh Medical Center, Pittsburgh

20037

George Washington University-Medical Faculty Associates, Washington D.C.

27403

Cone Health Cancer Center, Greensboro

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

27607

Rex Cancer Center, Raleigh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02768701 - Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter